Superior cell delivery features of genipin crosslinked polymeric microcapsules: preparation, in vitro characterization and pro-angiogenic applications using human adipose stem cells.
The ability of mesenchymal stem cells to self-renew and differentiate into specialized cell lineages makes them promising tools for regenerative medicine. Local injection and use of scaffolds had been employed earlier to deliver these cells; yet, an optimal delivery system remains to be identified. Here, using genipin, which is a non-toxic natural cross linker for proteins, we prepared alginate-chitosan polymeric microcapsules (GCAC) to develop an efficient stem cell delivery system. We investigated the properties of this membrane along with the encapsulated adipose tissue-derived stem cells (ASCs) and compared that with the widely used alginate poly-lysine (APA) membranes. The GCAC membrane was able to support cell viability, augment cell growth, and showed better results under external rotational and osmotic pressures with about 30% of the ruptured capsules in comparison to 60% ruptured APA capsules. The membrane also provided immune-protection to the entrapped cells as demonstrated by the lymphocyte proliferation assay. The capsule also has potential for long-term storage. The encapsulated four million ASCs also showed steady secretion of approximately 4600 pg vascular endothelial growth factor (VEGF) over 15-day time period comparable to that of free cells. Furthermore, the encapsulated ASCs showed around 3.8-fold increase in VEGF secretion after 72 h hypoxic conditions in comparison to normoxic conditions. This increased VEGF expression resulted in improved angiogenic potential of the bioactive capsules as noted by enhanced endothelial cell growth. GCAC encapsulation also did not show any effect on their differentiation ability. Thus, because of these biocompatible and bioactive attributes, genipin cross-linked polymeric microcapsules can emerge as a potentially important tool for improved stem cell-based therapy and cell delivery applications.
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada.
Arghya
A
Paul
Arielle
A
Cantor
Dominique
D
Shum-Tim
Satya
S
Prakash
D000273:Adipose Tissue / Q000166:cytology*; D000464:Alginates / Q000737:chemistry; D000818:Animals; D002214:Capsules / Q000009:adverse effects* / Q000737:chemistry*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D048271:Chitosan / Q000737:chemistry; D016228:Endothelial Growth Factors / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D006801:Humans; D057889:Iridoid Glycosides / Q000737:chemistry*; D039823:Iridoids; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D011108:Polymers / Q000737:chemistry*; D051381:Rats; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D014161:Transduction, Genetic
D000464:Alginates; D002214:Capsules; D016228:Endothelial Growth Factors; D006603:Hexuronic Acids; D057889:Iridoid Glycosides; D039823:Iridoids; D011108:Polymers; D020723:Glucuronic Acid; D048271:Chitosan; C007834:genipin